Sareum is an experienced and specialist Structure-based Drug Discovery company. We accelerate and improve the productivity of both our in-house and our partners' discovery research using our proprietary approaches.

Sareum has a highly experienced team with a track record of delivering high quality results for pharmaceutical and biotechnology clients.

Sareum is developing a robust pipeline of novel cancer drug candidates for partnering with pharmaceutical companies. We generate revenues to support this pipeline through the provision of our specialist discovery research services.

Sareum delivers results through the entire drug discovery value chain, from gene through to valuable preclinical candidate. We carry out complete structure-based discovery programmes for creating novel pre-clinical candidates as well as specific tailored projects to resolve clients' issues in gene to structure, structure to lead, and/or lead to candidate activities.

Sareum creates novel IP and highly valuable clinical candidates for our clients across a range of therapeutic areas. We are very flexible in our approach to how we structure our partnerships and can engage in fee-for-service, out-source research, technology transfer or joint research programmes.

Sareum is a public listed company and its shares are listed on the AIM market of the London Stock Exchange.

Sareum Holdings PLC
22 October 2007


For immediate release 22 October 2007





SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Fundraising

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that it has agreed to place 138,888,889
Ordinary Shares of 0.025p nominal value at a price of 0.9p per share to raise
1.25 million before expenses. 25,944,889 of these shares are being placed
subject to approval at the Company's AGM on 15 November 2007.

Mr and Mrs Leonard Licht have agreed to subscribe to 33,333,333 new Ordinary
Shares and together will hold 13.43% of the Company's enlarged issued share
capital1. The Directors of the Company have agreed to subscribe to 2,000,000 new
Ordinary Shares. The remainder is being placed with clients of the Company's
broker, Ellis Stockbrokers Limited.

Mr Leonard Licht is a Partner of Hg Capital and previously has been a former
founding director and Vice Chairman of Mercury Asset Management and the Deputy
Chairman of Jupiter Tyndall Group.

The funds raised from this share issue will used to advance the Company's
in-house development pipeline of cancer drug candidates and to provide
additional working capital.

The Directors share purchases are:
Name Number of shares Number of shares held Percentage of issued
purchased following share purchase share capital1
Dr Paul Harper 1,111,111 2,444,444 0.41%
Dr Tim Mitchell 111,111 42,780,471 7.15%
Mr Giorgio Reggiani 555,556 555,556 0.09%
Dr John Reader 111,111 43,447,111 7.26%
Dr David Williams 66,667 42,735,987 7.14%

Application has been made for the admission of 112,944,000 shares to trading on
AIM with admission expected to take place on 26 October 2007. Application will
be made for the admission of 25,944,889 shares to trading on AIM with admission
expected to take place on 21 November 2007.

1 Percentage of share capital assuming AGM approval for the issue of 25,944,889
new Ordinary Shares.

Commenting on the announcement, Sareum's Chief Executive Officer, Dr Tim
Mitchell said: "This placing will provide valuable funds to advance our in-house
cancer programs towards a stage where they become attractive licencing
opportunities. We are also very pleased that Mr and Mrs Licht have chosen to
increase their shareholding in Sareum."



For further information:


Sareum Holdings plc 01223 497700

Tim Mitchell, Chief Executive Officer
Buchanan Communications 020 7466 5000

Tim Anderson, Mary-Jane Johnson
Grant Thornton Corporate Finance 020 7383 5100

Philip Secrett, Colin Aaronson

Always encouraging to see major shareholders and directors increasing their stake. I hold these but don't check much as there's not much to get excited about yet----maybe we're approaching a turning point??

i think this bit is important:

Commenting on the announcement, Sareums Chief Executive Officer, Dr Tim Mitchell, said: These discoveries represent a significant development in Sareums internal drug candidate portfolio with key assets identified against important cancer drug discovery targets. We are actively seeking licencing partners for these programmes to assist the advancement of novel chemical series through to clinical candidate nomination.

plus events:
# Global Pharma R&D Summit North America 2007, Boston USA, Oct 22nd and 23rd 2007.
# BIO Europe, Hamburg, Germany, Nov 12th-14th 2007.

and finally: AGM 15th November

So hopefully end of October we will see little gain

many buyers today, looks like they expect something, or at lease they think that it's good moment to invest something in this company.

16:39 1.19p 7,240,588 86,163 Buy O
13:15 1.19p 4,854,999 57,774 Buy O
16:22 0.90p 5,750,000 51,750 Sell O
16:36 1.19p 3,315,000 39,448 Buy O
16:37 1.19p 1,965,000 23,384 Buy O

I noticed these buyers too, Fernandesb. Made an excellent profit with this share earlier in the year. Will probably buy some tomorrow, but would have to sell something first.

well, it is hard to say what is going on, all programs seems to be in start-middle stage , but maybe we don't know everything, i will support them just because of what they do

NB: I reckon that all the transactions at 1.10p this morning are Buys - I bought at that price, and the quote was 1-1.2 at the time (and has been all morning so far).

Sareum Holdings PLC
24 October 2007


Sareum Holdings plc ("Sareum" or the "Company")

Placing of shares

Application has been made for the admission of 112,941,176 shares to trading on
AIM with admission expected to take place on 26 October 2007.

The shares have been issued pursuant to the placing announced on 22 October
2007. The number of shares being admitted will be 112,941,176 shares and not
112,944,000 as previously announced. The balance of the placing shares,
amounting to 25,947,713 Sareum shares, will be issued subject to approval at
the Company's AGM on 15 November 2007.


For further information:

Sareum Holdings plc
01223 497700
Tim Mitchell, Chief Executive Officer

A lot more Buys again today - and this stock has been quite inactive I think for some time. I didn't have a lot of spare cash today but am pleased to have bought some at least. They're working with the right people on the research, so they'll be getting some worthwhile results that they can commercialise. Any good news is likely to be kept back until the AGM on 15 Nov I guess.

:) Toya, lets hope we are going to get some good news before 15 Nov and because AGM also, that's why i posted this thread as New Chance for Sareum, :):) i think it may be bright future for this one if things will go right

10m buy this morning!!!

Largest today:


Value Price Volume Time Buy/Sell Type
143,750 1.15p 12,500,000 10:11 Buy O
43,833 1.14p 3,845,000 16:33 Buy O
39,164 1.15p 3,405,556 10:11 Buy OK
35,796 1.14p 3,140,000 16:30 Buy O
19,984 1.14p 1,753,000 16:33 Buy O
12,426 1.14p 1,090,000 16:34 Buy O

well, will see:)

I've spoken to people from Sareum and broker also, they didn't have any problems o find investors for new placings, hopefully money they were rising gonna help to push this company to the next level.

Sareum Holdings PLC
16 November 2007



For immediate release 16 November 2007


Sareum Holdings plc

("Sareum" or "the Company")


Appointment of Dr Alastair Riddell as Non-Executive Director


Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce the appointment of Dr Alastair Riddell as
Non-Executive Director with immediate effect.

Alastair James Riddell, aged 58, was previously Chief Executive Officer of
Paradigm Therapeutics Limited, the drug target discovery and development company
that was acquired by Takeda Pharmaceutical Company in March 2007.

He was also previously Chairman of Surface Therapeutics Limited, the drug
discovery and development company that has now been acquired by Serentis.

Prior to that Dr Riddell was the Chief Executive Officer of Pharmagene plc, the
drug discovery company, for seven years, where he raised 8.6 million in a
private placement in 1999 and 41.7 million at IPO in July 2000.

He has also held senior positions in international marketing, sales and general
management in Amersham International and Centocor. He also previously directed
the medical departments of Celltech and Centocor Europe.

Dr Riddell was Deputy Chairman of the BioIndustry Association (BIA) and was a
member of the executive board of the BIA for 3 years. Dr. Riddell was a
practising physician before entering the pharmaceutical industry over twenty
years ago.

The directors of Sareum believe that Dr. Riddell brings a wide range of industry
experience to the Company and consider him a valuable addition to the Board.

Commenting on this announcement, Sareum's Chairman, Dr Paul Harper, said: "I am
delighted to announce that Alastair has joined Sareum's Board. He is a seasoned
biotech entrepreneur with significant Board level experience and will be
instrumental in helping to steer the progress of Sareum."

Dr. Riddell has, in the previous five years, been a director of the following
companies:

Current directorships Previous directorships
none Surface Therapeutics Limited
Paradigm Therapeutics Limited
Pharmagene plc
Pharmagene Laboratories Trustees Limited
Pharmagene Therapeutics Limited
BioIndustry Association


The Company confirms there is no other information that falls to be disclosed
under Schedule 2 paragraph (g) of the AIM Rules.

For immediate release 15 November 2007


SAREUM HOLDINGS PLC
("Sareum" or "the Company")

AGM Statement


At the Company's annual general meeting held today, the following resolutions
were passed unanimously by shareholders on a show of hands.


The proxy votes received prior to the meeting on each resolution were as
follows:

ORDINARY RESOLUTIONS Votes Discretion Votes Votes
For Against Withheld

1.To receive and adopt the
Directors' report
and financial statements for the year 8,724,070 221,058 0 0
ended 30 June 2007. 97.53% 2.47% 0% 0%


2. To receive and adopt the
Remuneration
Committee report for the year ended 8,679,070 266,058 0 0
30 June 2007. 7.03% 2.97% 0% 0%


3.To re-elect Dr Paul Harper 8,724,070 221,058 0 0
as Director. 97.53% 2.47% 0% 0%


4.To re-elect Mr Giorgio
Reggiani as 8,576,070 366,058 3,000 0
Director. 95.88% 4.09% 0.03% 0%


5.To re-appoint Shipleys LLP
as auditors and
authorise the Directors to fix their 8,721,070 221,058 3,000 0
remuneration. 97.50% 2.47% 0.03% 0%

6.To authorise Directors for the
purposes of
section 80 of the Companies Act 1985
(the
Act) to allot relevant securities
(within 8,531,070 366,058 48,000 0
the meaning of that section) up to an 95.37% 4.09% 0.54% 0%
aggregate nominal amount of 90,000.



SPECIAL RESOLUTIONS Votes Discretion Votes Votes
For Against Withheld
7.Subject to the passing of resolution
6, to
authorise Directors, in accordance
with
section 95 of the Act, to allot
equity
securities (as defined in section 94
of
the Act) wholly for cash up to an 8,531,070 321,058 93,000 0
aggregate nominal amount of 50,000. 95.37% 3.59% 1.04% 0%


8.To authorise the Company to send or
supply
documents or information to
shareholders
by making them available on the 8,549,070 266,058 130,000 0
Company's 95.58% 2.97% 1.45% 0%
website or other electronic means.

For further information please contact:

Sareum Holdings +44 (0) 1223 497700

Tim Mitchell, Chief Executive Officer

Buchanan Communications +44 (0) 20 7466 5000


Tim Anderson, Mary-Jane Johnson

and 5% up today, :):)

Fernandes: the new appointment sounds good. I didn't manage to motor down to the AGM yesterday - would have been interesting.

Didn,t know that u planned to, I was at work all day so i had no chance for it

Sareum Holdings PLC
18 November 2007



Sareum Holdings plc

Director's shareholding


Sareum Holdings plc (the "Company") was informed on 16 November 2007 that on 16
November 2007 a director of the Company, Dr Alastair Riddell, purchased
1,000,000 ordinary shares of 0.025p of the Company ("Ordinary Shares") at a
price of 0.94p per Ordinary Share.

Dr Alastair Riddell now holds 1,000,000 Ordinary Shares representing 0.17 per
cent. of the Company's total voting rights.



Nice to see a bit of director confidence.

Yes indeed!